Feasibility and safety of cryoballoon ablation for atrial fibrillation and closing patent foramen ovale without implantation: A pilot study
Heart Rhythm · 2024
DOI: 10.1016/j.hrthm.2024.06.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart Rhythm, 2024. Verfasst von Jiang Deng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Yongchuan Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cryosurgery, Foramen Ovale, Patent, Feasibility Studies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Patent foramen ovale (PFO) affects 20%-34% of adults and is associated with strokes and other disorders. The conventional treatment of PFO-related strokes is a closure procedure. The metal device is associated with some adverse events. OBJECTIVE: Our aim was to investigate the efficacy and safety of PFO closure using cryoablation without implantation in patients with atrial fibrillation (AF) who underwent pulmonary vein isolation (PVI). METHODS: We divided the 22 patients with both PFO and AF who underwent PVI via cryoablation into 2 groups: standard PVI + atrial septal (AS) cryoablation group (group 1, n = 11) and standard PVI group (group 2, n = 11). The guidewire accesses the left atrium through the PFO without AS puncture during the procedure. Standard PVI via cryoablation was performed. The cryoballoon was retracted to the right atrium and inflated against the AS post-PVI. Patients in group 1 had cryoablation for 120-150 seconds, whereas patients in group 2 received sham ablation. The co-primary end points were the PFO closure rate and a composite of AF recurrence and stroke/transient ischemic attack (TIA) events. RESULTS: There were no differences in procedure-related adverse events between the 2 groups. Neither group had an ischemic stroke report at 1-year follow-up. The PFO closure rate at 6 months in group 1 was significantly higher than that in group 2 (7 [63.6%] vs 1 [9.1%]; P = .002). AF recurrence post ablation was comparable in both groups at 3 months (3 [27.3%] vs 1 [9.1%]; P = .269), 6 months (0 vs 0), and 12 months (2 [18.2%%] vs 1 [9.1%]; P = .534) of follow-up. CONCLUSION: Cryoablation is a safe and effective approach to close PFO in patients with AF undergoing PVI in a single procedure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
- Department of Cardiovascular Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Cardiovascular Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: jiafengpeng72@126.com.
Zitieren
APA
Deng, J., Wang, E., Liu, G., Qin, C., Dong, Q., Yang, W., Wang, Y., Abdul Qadir, R., & Jia, F. (2024). Feasibility and safety of cryoballoon ablation for atrial fibrillation and closing patent foramen ovale without implantation: A pilot study. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2024.06.006
Vancouver
Deng J, Wang E, Liu G, Qin C, Dong Q, Yang W, et al. Feasibility and safety of cryoballoon ablation for atrial fibrillation and closing patent foramen ovale without implantation: A pilot study. Heart Rhythm. 2024. doi:10.1016/j.hrthm.2024.06.006
BibTeX
@article{Deng2024,
author = {Deng, Jiang and Wang, EnRun and Liu, Gang and Qin, ChunChang and Dong, Qian and Yang, Wei and Wang, YanFei and Abdul Qadir, Rana and Jia, Fengpeng},
title = {Feasibility and safety of cryoballoon ablation for atrial fibrillation and closing patent foramen ovale without implantation: A pilot study},
journal = {Heart Rhythm},
year = {2024},
doi = {10.1016/j.hrthm.2024.06.006}
}
EUVIMED